Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,901–2,000 of 2,932
Obiajunwa, C., Chidebelu, P. E., & Nweze, E. I. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107792 · Cited by 2
Akinbobola, A., Shilla, D. J., Shilla, D. A., & Quilliam, R. S. (2025) · Biologia · doi:10.1007/s11756-025-01981-w · Cited by 3
Campanella, J. E. M., Rosa, L. T., & Malavazi, I. (2025) · mBio · doi:10.1128/mbio.00803-24 · Cited by 3
“The landscape of fungal diseases has undergone significant transformations in recent decades, fueled by the emergence of critical pathogens like Candida auris and the re-emergence of well-recognized pathogens driven by the recurrent identification of antifungal-resistant strains worldwide (3, 5).”
Virulence and pathogenicity of secondary fungal infections
Murugavel, A., & Ramakrishnan, J. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2537423 · Cited by 6
“…the global toll of fungal infections has surged dramatically, with reported deaths soaring from 1.5 million in 2017 to 3.8 million in 2024 (Bongomin et al. 2017; Denning 2024). this dramatic rise in fungal infection-related deaths is likely driven by a combination of factors, including…”
InfluentialBoman, J. H., Souza, N., Light, J., Holt, D., Jones, S., King, A., Berryman, M., Shuda, S. A., Borrelli, M., Logan, B. K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326200 · Cited by 2
“Four Candida species, including C. parapsilosis , were noted in the WHO list because these organisms are increasingly causing infections [38,39] and outbreaks [40–43] and have evolved resistance to the few anti-fungal agents that are available for treatment [44,45].”
Dán, K., Zsindely, N., Kele, Z., Laczi, K., Karemera, K. J., Papp, C., Farkas, A., Maróti, G., Borics, A., Bodai, L., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146558 · Cited by 4
Tian, R., Bai, Q., Xu, T., Richardson, M. D., de Hoog, S., Jin, Y., Zhou, S., Li, R., & Song, Y. (2025) · Mycopathologia · doi:10.1007/s11046-025-00982-2 · Cited by 2
“In recent years, fungal infections have gradually attracted widespread attention globally[1], especially in China[2], where the incidence of fungal infections has significantly increased in recent years, particularly due to advancements in medical technology and shifts in disease patterns, as…”
Antwi‐Boasiako, M. N., Ayensu, F., Awuah, A., Mutala, A., Boampong, K., & Badu, K. (2025) · MicrobiologyOpen · doi:10.1002/mbo3.70028 · Cited by 4
“Recent studies however, point to an increase in the percentage of Candida ‐ caused UTI compared to UTI caused by bacteria particularly in hospitalized patients (Fisher et al. 2011; Bongomin et al. 2017; Gharanfoli et al. 2019; Gajdács et al. 2019).”
Human-like Biofilm Models to Study the Activity of Antifungals Against Aspergillus fumigatus
Furnica, D.-T., Falkenstein, J., Dittmer, S., Steinmann, J., Rath, P., & Kirchhoff, L. (2025) · Microorganisms · doi:10.3390/microorganisms13092040 · Cited by 2
“Aspergillus fumigatus can be considered as one of the most prevalent fungal opportunistic pathogens present in clinics [1].”
Zhang, M., Ma, W., Wang, J., Yang, F. J., Zhong, J., & Xu, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1664896 · Cited by 2
Willmann, A.-C., Berkenfeld, K., Boeck, G., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107305 · Cited by 2
Cryptococcus displays spore-specific uptake by alveolar epithelial cells
Ortiz, S. C., Fortune‐Grant, R., Thom, A., Davies, J., May, R. C., Drummond, R. A., & Bertuzzi, M. (2025) · mBio · doi:10.1128/mbio.01831-25 · Cited by 2
Pablo-Hernando, E., Alcón, J., Riesgo, M. J., et al. (2025) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2025.09.001 · Cited by 2
Cytosolic receptors and signaling in antifungal immunity
Khau, S., Désoubeaux, G., Si‐Tahar, M., Biquand, É., & Briard, B. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00627-6 · Cited by 3
“Therefore, fungi have been increasingly recognized as a major healthcare issue in recent years (Bongomin et al, 2017; Brown et al, 2012).”
Ahmadnezhad, R. S., Shams‐Ghahfarokhi, M., Jamzivar, F., Eslamifar, A., Sohrabi, A., & Razzaghi‐Abyaneh, M. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04662-7 · Cited by 5
“Immunosuppressed patients are more susceptible to systemic and invasive fungal infection (IF), such as Candida auris , Cryptococcus neoformans , and Aspergillus fumigatus , that classified as top-priority fun - gal infections (Bongomin et al. 2017; Sati H 2022).”
Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein
Bregón-Villahoz, M., Díez, A., Galech, J., Cuétara, M. S., Carrano, G., Moragues, M. D., Fernandez-de-Larrinoa, Í., & Arrieta-Aguirre, I. (2025) · Mycopathologia · doi:10.1007/s11046-025-01025-6 · Cited by 5
Prevalent fungal pathogens and antifungal resistance in Lebanon: A scoping review
Khachab, Y., Ghader, M. B., Tahesh, V., Khoumassi, R., & Sokhn, E. S. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103062 · Cited by 2
Wang, X., Zhang, Y., Sunderiya, G., Xin, Z., Ji, Y., Yang, S., Han, D., Chen, X., Shao, D., Shi, J., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.063 · Cited by 3
“Globally, an estimated 150 million cases of severe fungal infections and 1.5 million related deaths are reported annually [1], with candidiasis being the predominant contributor.”
InfluentialSafaat, M., Rachmayati, R., Wakabayashi, R., et al. (2025) · RSC Applied Interfaces · doi:10.1039/d5lf00298b · Cited by 2
Zheng, X., He, X., Song, Z., Chen, W., & Liu, F. (2025) · Virulence · doi:10.1080/21505594.2025.2600158 · Cited by 2
“Untreated IPA results in a 40–70% mortality rate, only reducing to 30–50% with antifungal therapy (higher in immunocompromised hosts) [49,50].”
Cornely, O. A., Bassetti, M., García‐Vidal, C., Hoenigl, M., Maertens, J. A., Martín‐Loeches, I., Mira, J. P., & White, P. L. (2025) · Mycoses · doi:10.1111/myc.70135 · Cited by 4
“Candidaemia predominantly affects critically ill and immunocompromised patients, with 60% of cases arising in ICUs [9].”
Wang, H., Wang, H., Yang, Y., Wang, T., Wang, C., Wu, D., Zheng, C., & Wei, W. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00749 · Cited by 4
Boddu, V. B., Vudari, B., Vaddi, P. R. R., Allaka, T. R., Koduri, G. B., & Bollikolla, H. B. (2025) · ChemistrySelect · doi:10.1002/slct.202503569 · Cited by 3
CAR-T therapy: Advances in respiratory diseases
Han, H., & Hu, Y. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.11.001 · Cited by 3
Xu, Q., Yan, Q., Guan, M., Liu, M., Wei, S., Cao, Y., Jiang, X., Lu, W., & Zha, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004587 · Cited by 4
“…Africa, the Middle East, and South Asia reflects challenges with nosocomial outbreaks and environmental persistence [ 65–67 ] , while the burden of invasive candidiasis is often higher in regions with limited healthcare resources, where delayed diagnosis contributes to severe outcomes [ 68 , 69 ] .”
Chemical Characteristics and Biological Potential of Prunus laurocerasus Fruits
Todorova, M. M., Petkova, N., Ivanov, I., Tumbarski, Y. D., Yanakieva, V., Vasileva, I., Barakova, Y., Cherneva, E. D., & Nikolova, S. (2025) · Life · doi:10.3390/life15121847 · Cited by 4
“Approximately 1.6 million people die each year from fungal infections, which is more than three times the projected number of deaths from malaria and comparable to tuberculosis [26].”
InfluentialStructural basis of product recognition by Mycobacterium tuberculosis fatty acid synthase
Samani, E. K., Hasan, S. M. N., Keszei, A. F. A., et al. (2025) · Protein Science · doi:10.1002/pro.70412 · Cited by 2
Ren, Y., Qin, J., Li, M., & Shen, F. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07370 · Cited by 3
Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi
Faguy, F. S., Walczak, M. A. A., & Barker, B. M. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-25 · Cited by 2
“Histoplasmosis is among the most common pulmonary mycoses; in 2017 alone, global histoplasmosis infection totaled an estimated 500,000 cases, and global disseminated histoplasmosis was estimated at 100,000 cases (58).”
Pellón, A., Nasab, S. D. S., Bidkhori, G., Griffiths, J. S., Vaga, S., Begum, N., Blagojevic, M., Sigh, N. K., Kotowicz, N. K., Uzochukwu, I., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea0405 · Cited by 7
“The high prevalence and morbidity of mucosal and systemic candidiasis make C. albicans the most clinically relevant fungal pathogen ( 18 – 20 ).”
“Should I stay or should I go”—a kinase delays escape of Candida glabrata from macrophages
Lange, T., Clairet, C., Fischer, L., Vij, R., Sonnberger, J., Mantke, J., Jablonowski, N., Seemann, E. A., Qualmann, B., d’Enfert, C., et al. (2026) · mBio · doi:10.1128/mbio.03885-25 · Cited by 3
Mies, K., Hermes, G., Beckers, J., Mörgelin, M., Simon, M., Ruegamer, T., Jantsch, J., Klatt, A. R., Streichert, T., & Elezagic, D. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1756518 · Cited by 3
Emerging mycoses: a neglected area of concern for global health
Barac, A. M., Cornely, O. A., Paño-Pardo, Gupta, N. D., Jokelainen, P., Mora-Rillo, M., Tsiodras, S., Gkrania‐Klotsas, E., Bulescu, C., Pellejero-Sagastizábal, G., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.03.013 · Cited by 4
Štrimaite, M., Bailey, H., Keyhanfar, D., Lee, R., & Williams, G. R. (2026) · Pharmaceuticals · doi:10.3390/ph19030478 · Cited by 2
High‐Volume Culture Improves Diagnostic Yield of Aspergillus Species From Sputum
van Haren, M. H. I., Michon, L. A., Verweij, P. E., Reijers, M. H. E., Brüggemann, R. J. M., van Mook-Vermulst, S. V. M., van der Lee, H., Melchers, W. J. G., Pas, S. D., & Buil, J. B. (2026) · Mycoses · doi:10.1111/myc.70168 · Cited by 2
“These considerations are particularly relevant for resource-limited settings, where incubator space, consumables and staff capacity may be constrained [19].”
Liu, H., Wang, C., Huang, W., Hu, S., & Huang, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788786 · Cited by 3
Dahdah, M., Ettouil, Y., Issa, H., Koussih, L., Almutairi, M. H., Rouabhia, M., & Semlali, A. (2026) · Antibiotics · doi:10.3390/antibiotics15040420 · Cited by 2
“Although fungi represent a relatively small proportion of the human microbiome, opportunistic fungal pathogens can cause a wide range of mucosal and systemic infections, particularly in immunocompromised individuals [2,3].”
Vitamin D–AMP axis in host defense against fungal infections
Akimbekov, N. S., Digel, I., Sakhanova, S., Tastambek, K. T., Sherelkhan, D. K., & Razzaque, M. S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1807743 · Cited by 4
Lipid-based nanocarriers for antifungal drug delivery
Staniszewska, A., Kala, D., Kuryk, Ł., Borkowska, A. M., Kuma, S., & Staniszewska, M. (2026) · Discover Nano · doi:10.1186/s11671-026-04676-6 · Cited by 3
“According to the World Health Organization's [153] fungal priority pathogens list, fungal diseases (FDs) represent a growing global health threat, responsible for approximately 1.5–2 million deaths annually [26, 153].”
InfluentialRivas-Pinedo, P., & Oñate, J. (2026) · Journal of Fungi · doi:10.3390/jof12070498 · Cited by 4
Albakri, A. (2019) · Research and Review Insights · doi:10.15761/rri.1000151 · Cited by 3
“Immune deficiency: The main factors contributing to the rise of fungal infection include: (i) an increase in the incidence of diseases causing immune dysfunction; and (ii) an increase in the medical use of a broad range of antibiotics, cardiac surgery and intravenous use of drugs [2,4,7,8].”
BackgroundHakim, Z. T., Alizadeh, F., Kokhdan, E. P., & Khodavandi, A. (2020) · ACTA Pharmaceutica Sciencia · doi:10.23893/1307-2080.aps.05811 · Cited by 2
Heroine, M. M., Baptiste, H. F. J., Yimgang, V. L., et al. (2020) · European Journal of Biology and Biotechnology · doi:10.24018/ejbio.2020.1.5.72 · Cited by 2
“Mycoses still one of the major health issues in the world [1].”
BackgroundFungal infections: advances in diagnosis and treatment
Vijayaraman, R. S., & Pushpanathan, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821734-4.00011-3 · Cited by 2
Antioxidant and anti-candida activity of selected medicinal plants of Indian origin
Prajapati, S., Bhardwaj, A., & Gupta, P. K. (2020) · Herba Polonica · doi:10.2478/hepo-2020-0016 · Cited by 2
Zver, S., Avčin, S. L., Bedreag, O. H., Bizilj, S., Ecrulj, V., Jazbec, J., Puconja, N., Stanić, R., & Jereb, M. (2021) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12755 · Cited by 2
“Invasive candidiasis (IC) remains a leading cause of opportunistic fungal infection in hospitals and is associated with substantial morbidity and mortality [2,8], with an estimated ~700,000 cases occurring globally each year [9].”
BackgroundLuberto, L., Neroni, B., Gandini, O., Fiscarelli, E. V., Salvatori, G., Roscilli, G., & Marra, E. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.789774 · Cited by 2
Role of probiotics in the management of fungal infections
Chaudhari, A., Bharti, A. H., & Dwivedi, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823733-5.00015-5 · Cited by 3
Sharma, M. K. M. G., Das, A. K. A., Singh, S. M. D., et al. (2022) · International Journal of Current Microbiology and Applied Sciences · doi:10.20546/ijcmas.2022.1102.006 · Cited by 2
N-Phenacyldibromobenzimidazoles—Synthesis Optimization and Evaluation of Their Cytotoxic Activity
Kowalkowska, A., Chojnacki, K., Multan, M., Maurin, J. K., Łukowska‐Chojnacka, E., & Wińska, P. (2022) · Molecules · doi:10.3390/molecules27144349 · Cited by 4
Balkenhol, J., Bencúrová, E., Gupta, S. K., Schmidt, H., Heinekamp, T., Brakhage, A. A., Pottikkadavath, A., & Dandekar, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.050 · Cited by 3
“fumigatus can cause life-threatening infections with more than 3,000,000 cases per year [7].”
BackgroundMunir, G., Farhad, S., Alam, S., Azim, A., Hussain, S., Khan, S. A., Raziq, K., Bangash, S. A., Llah, I.-U., & Mir, H. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22167634 · Cited by 2
Mechanism of action of antifungal agents
Jana, S., Gayen, S., Kumari, R., Patra, S., Haldar, P. K., Bhowmik, R., Shaharyar, M. A., Mandal, A., Mazumdar, H., & Karmakar, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00019-1 · Cited by 4
Effects of Natural Borneol on Germ Tube Formation and Preformed Biofilm Activity in Candida albicans
Wang, Y., Liu, H., & Zhan, F. (2022) · Natural Product Communications · doi:10.1177/1934578x221129128 · Cited by 2
“However, in immunocompromised patients, its overgrowth can cause a wide range of infections, ranging from superficial to septicemic candidiasis.(2) Candidiasis and disseminated candidiasis together have a mortality rate of 40% and are the second leading cause of death from nosocomial infections in the United States.”
BackgroundOñate, J., Rivas-Pinedo, P., Saavedra-Trujillo, C. H., Camacho‐Moreno, G., Cuervo, S. I., Enciso-Olivera, L. J., Patiño-Escobar, B., Osorio, J. P., Berrío, I., Álvarez, C., et al. (2022) · Infectio · doi:10.22354/24223794.1064 · Cited by 2
Filth Flies As Carriers of Intestinal Parasites And Fungi in a Tertiary Institution in Ghana
Addo, S. O., Oppong, J., Achawe, E. M., Nketia, B. B., Agyei, P. B., & Larbi, J. A. (2022) · Journal of Medical Microbiology and Infectious Diseases · doi:10.52547/jommid.10.4.179 · Cited by 2
Evaluation of the Synthetic Multifunctional Peptide Hp-MAP3 Derivative of Temporin-PTa
Silva, P. S. E., Guindo, A. S., Cardoso, P. H. D. O., de Moraes, L. F. R. N., Boleti, A. P. D. A., Ferreira, M. A., de Oliveira, C. F. R., Macedo, M. L. R., Rossato, L. L., Simionatto, S., et al. (2023) · Toxins · doi:10.3390/toxins15010042 · Cited by 3
“The incidence of fungal infections is overwhelming in pharmaceutical, medical, and basic science [60,61].”
BackgroundHistoplasmosis - A Comprehensive Study of Epidemiology, Pathogenesis, Diagnosis, and Treatment
Danteș, E., & Dumea, E. (2023) · Infectious diseases · doi:10.5772/intechopen.104142 · Cited by 3
Dudhwadkar, S., Salunkhe, A., Tandon, S. A., & Goyal, N. (2023) · Chemical Papers · doi:10.1007/s11696-023-02720-8 · Cited by 2
Çuhadar, T., Kalkancı, A., Tunçcan, Ö. G., Yeğin, Z. A., Özkurt, Z. N., Köktürk, N., & Yağcı, M. (2023) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20239921 · Cited by 2
Long-read Sequencing and de novo Genome Assembly of Three Aspergillus fumigatus Genomes
Hemmings, S., Rhodes, J. L., & Fisher, M. C. (2023) · Mycopathologia · doi:10.1007/s11046-023-00740-2 · Cited by 3
“fumigatus can cause invasive and chronic forms of the disease aspergillosis which results in more than 300,000 deaths per year [2].”
BackgroundLieberman, J. A., & Bourassa, L. A. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00471-3 · Cited by 2
Makedonova, Y. А., Гаврикова, Л. М., Dyachenko, S. V., et al. (2023) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2023-30-4-48-60 · Cited by 2
Fartyal, M. (2023) · Vegetos · doi:10.1007/s42535-023-00756-5 · Cited by 4
“According to Bongomin et al. (2017), the primary etiologic Candida species linked to nosocomial invasive candidias is worldwide is Candida albicans .”
Antimicrobial Peptides—Membrane Interactions
Lyu, Y., & Narsimhan, G. (2023) · ACS symposium series · doi:10.1021/bk-2023-1457.ch014 · Cited by 3
Bhalla, D., Dinesh, S., & Sharma, S. (2023) · Current Nanomaterials · doi:10.2174/0124054615257633231128051924 · Cited by 2
Case Report: Diagnosing Dermatophytoses in Children
Bulińska, B., Purzycka-Bohdan, D., Rychlik, K., Anzelewicz, S., & Nowicki, R. J. (2024) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2023.10.008 · Cited by 2
Cutaneous disseminated sporotrichosis in an immunocompetent farmer
Rakotoarisaona, M. F., Andrianarison, M., Sendrasoa, F. A., et al. (2024) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2023.100626 · Cited by 2
Vázquez-Prieto, S., Liste, A. V., & Paniagua, E. (2024) · Diseases · doi:10.3390/diseases12010022 · Cited by 3
“This is congruent with the high prevalence of superficial nail and skin fungal infections and the importance of using this drug in their treatment [10,32].”
BackgroundA One-health Approach to Combat Common Pet-associated Fungal Zoonosis
(2023) · International Journal of Agriculture and Biosciences · doi:10.47278/book.zoon/2023.181 · Cited by 2
Benefits of early antifungal therapy in hematology patients
Andreev, S. S., Бронин, Г. О., Epifanova, N. Y., Kozlova, O. P., Пристанскова, Е. А., Khostelidi, S. N., & Витальевна, Ш. О. (2024) · Oncohematology · doi:10.17650/1818-8346-2024-19-1-99-112 · Cited by 2
Emanghe, U. E., Imalele, E. E., Ogban, G. I., Owai, P. A., & Abraka, B. A. (2024) · Annals of African Medicine · doi:10.4103/aam.aam_82_23 · Cited by 4
The Influence of Dioxolane Ring Conjugates on Biological Activities: A Review Study
Bashir, M. K., Oglah, M. K., Mustafa, Y. F., et al. (2023) · Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ · doi:10.33899/iphr.2023.142073.1051 · Cited by 2
“These facts help scientists develop more potent compounds with fewer side effects (46-51).”
BackgroundAssi, S. R., & Al-Aaraji, A. S. (2024) · Iraqi Journal of Science · doi:10.24996/ijs.2024.65.3.7 · Cited by 2
“The incidence of severe fungal infections caused by opportunistic fungi has raised in recent years, especially in immunocompromised patients and endemic mycoses remain a major public health problem in several countries [1].”
BackgroundRemodeling of membrane lipid homeostasis in azole resistant isolates of Candida albicans
Usmani, S. A., Arya, K., Ali, B., Chandra, S., Chaturvedi, S., Bhardwaj, N., Prasad, R., & Singh, A. (2024) · Chemical Biology Letters · doi:10.62110/sciencein.cbl.2024.v11.658 · Cited by 3
Skin Disease in Tropics: Impacted by Heat, Humidity, and Healthcare Neglect
Sharma, A., & Gupta, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0411-8_16 · Cited by 4
Bu, F.-Z., Meng, S.-S., Wang, L., Wu, Z., & Li, Y. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.124403 · Cited by 2
Herbal formulations for the treatment of fungal infection
Patel, M., Patel, K., Bera, K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15383-9.00030-5 · Cited by 3
Candidiasis in Choloepus sp.—A Review of New Advances on the Disease
Benarrós, M. S. C., & Salvarani, F. M. (2024) · Animals · doi:10.3390/ani14142092 · Cited by 5
“In developing countries, the burden of Candida infections is also significant, often exacerbated by limited access to healthcare and diagnostic facilities [3,4,9].”
BackgroundPasman, R., Zhang, J., Zaat, S. A. J., Brul, S., & Krom, B. P. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.00360-24 · Cited by 4
“S. aureus and C. albicans are common instigators of bacterial and fungal BSIs, respectively (12, 70).”
Río, M. D., Radicioni, M. B., Cutine, A. M., Mariño, K. V., Mora-Montes, H. M., Cagnoni, A. J., & Regente, M. C. (2024) · Glycobiology · doi:10.1093/glycob/cwae058 · Cited by 2
da Cruz, R. P., Nascimento, L. L. L., da Silva, N. O., Felício, M. F., Macêdo, M. J. F., da Anunciação, J. A. O., Melo, B. F., Leandro, C. D. S., Filho, A. M., Moreira, F. C., et al. (2024) · SVOA Microbiology · doi:10.58624/svoamb.2024.05.046 · Cited by 2
“Among the most virulent fungal pathogens are Candida spp., Cryptococcus neoformans , and Aspergillus spp. [23].”
IFN Receptor 2 Regulates TNF-α–Mediated Damaging Inflammation during Aspergillus Pulmonary Infection
Rynda‐Apple, A., Servin, J. R., Lenz, J., Roemer, J., Benson, E. E., Hall, M. N., & Shepardson, K. M. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2200686 · Cited by 2
Synthesis, Copper(II) Binding, and Antifungal Activity of Tertiary N-Alkylamine Azole Derivatives
Pissarro, T., Malta-Luís, C., Ferreira, L., Pimentel, C., & Lima, L. M. P. (2024) · Inorganics · doi:10.3390/inorganics12090242 · Cited by 2
Zhu, B., Zhu, J., Sheng, L., Yao, Y., & Zhou, H. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s479714 · Cited by 2
“7 CPA has been regarded as an emerging fungal infectious disease with public health importance, therefore, early diagnosis and timely treatment are essential to reduce mortality and improve the prognosis of CPA.”
BackgroundNaamidine A reveals a promising zinc-binding strategy for topical antifungal therapy
Puumala, E., Nabeela, S., Thornburg, C. C., Grkovic, T., Uppuluri, P., Whitesell, L. J., O’Keefe, B. R., Robbins, N., & Cowen, L. E. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01194-24 · Cited by 4
Epigallocatechin gallate and its antifungal profiles
Murtiastutik, D., Bintanjoyo, L., & Wibisono, Y. (2024) · Tea in Health and Disease Prevention · doi:10.1016/b978-0-443-14158-4.00036-1 · Cited by 2
Yang, C.-Z., Xiong, J., Wang, J., Bi, H., Fu, J., Liu, X., Long, C., Zhang, Q., He, D., Tang, Y., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.005 · Cited by 2
Molecular Insights Into the Interplay Between Host Platelets and Fungal Pathogens
Kumari, N., Maharaj, S., Chattopadhyay, R., Singh, S. K., & Bari, V. K. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00237-6 · Cited by 2
“According to recent studies, around 1.9 million patients get an acute invasive fungal infection (IFI) each year, with an estimated 3 million people worldwide suffering from chronic severe fungal infections [1].”
InfluentialHanafy, D. M., & Leaver, D. J. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00568 · Cited by 3
Recognizing the Importance of Public Health Mycology
Bongomin, F. (2025) · Life · doi:10.3390/life15020145 · Cited by 3
“Further, access to quality antifungal drugs and diagnostic tests is limited, particularly in low-resource settings, where the fungal disease burden is the highest [12].”
Self-citationGlobal burden of reported lower respiratory system fungal infection
Wang, Z., Pan, M., & Zhu, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1542922 · Cited by 6
AlSaleh, A., & Shahid, M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10680-5 · Cited by 2
“The scarcity of epidemiological reports and the perceived regional low incidence of non-Candida mycosis may lead to it being overlooked in clinical care [1].”
InfluentialMastrella, C., Rizzo, S., Vito, M. D., Garzoli, S., Mercurio, M. D., Mariotti, M., Sorda, M. L., Zhiri, A., Sanguinetti, M., & Bugli, F. (2025) · Pharmaceuticals · doi:10.3390/ph18030321 · Cited by 5
Beyond Restoration: Coral Microbiome Biotechnology
Couceiro, J. F., Costa, R., & Keller‐Costa, T. (2025) · Coral reefs of the world · doi:10.1007/978-3-031-76692-3_15 · Cited by 3
Cai, R., He, C., Kong, Q., Lü, L., & Sang, H. (2025) · Current Microbiology · doi:10.1007/s00284-025-04150-z · Cited by 4
“Particularly concerning in immunocompromised individuals, invasive pulmonary aspergillosis (IPA) is a significant cause of morbidity and mortality, with an estimated 250,000 cases globally each year [1] and reported mortality rates ranging from 44 to 80% [2–5].”
Thymus vulgaris L. (Thyme): A herbal remedy against fungal infections
Kumar, D., Ansari, A., Bajpai, A. B., Rai, N., & Kumar, N. (2025) · Environment Conservation Journal · doi:10.36953/ecj.30233158 · Cited by 2
“According to recent estimates (Benedict et al. , 2017; Bongomin et al. , 2017; Wan Ismail et al. , 2020), more than three hundred million people suffer from serious fungal infections, which lead to more than 1.6 million deaths annually.”
InfluentialKılıç, C. S., Catarino, I., Alves-Silva, J. M., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14040343 · Cited by 2
Pérez-Camacho, P., Vargas-Moran, C., Torres-Cánchala, L., Ariza-Insignares, C., Sandoval-Calle, L. M., Gómez, I. E., Solís-Núñez, P., Cedeño-Castaño, J. V., Aguilar-Gonzalez, A. M., & Patiño, J. (2025) · Biomédica · doi:10.7705/biomedica.7444 · Cited by 2
Wang, D., Guan, L., Yin, Q., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03700-2 · Cited by 2
“…suggest PJP ranks among the top three most prevalent opportunistic fungal infections, alongside invasive candidiasis and invasive aspergillosis [14], with affected patients frequently requiring ICU admission and mechanical ventilation during hospitalization, and experiencing high mortality…”
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.